NASDAQ:RGEN • US7599161095
Taking everything into account, RGEN scores 5 out of 10 in our fundamental rating. RGEN was compared to 57 industry peers in the Life Sciences Tools & Services industry. RGEN has an excellent financial health rating, but there are some minor concerns on its profitability. While showing a medium growth rate, RGEN is valued expensive at the moment.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.66% | ||
| ROE | 2.32% | ||
| ROIC | 1.65% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.03% | ||
| PM (TTM) | 6.62% | ||
| GM | 52.65% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.91 | ||
| Altman-Z | 5.95 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.37 | ||
| Quick Ratio | 7.12 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 69.66 | ||
| Fwd PE | 59.82 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 73.18 | ||
| EV/EBITDA | 47.9 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:RGEN (3/3/2026, 11:02:33 AM)
119.12
-5.85 (-4.68%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 69.66 | ||
| Fwd PE | 59.82 | ||
| P/S | 9.09 | ||
| P/FCF | 73.18 | ||
| P/OCF | 57.15 | ||
| P/B | 3.19 | ||
| P/tB | 11.08 | ||
| EV/EBITDA | 47.9 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.66% | ||
| ROE | 2.32% | ||
| ROCE | 2.11% | ||
| ROIC | 1.65% | ||
| ROICexc | 2.27% | ||
| ROICexgc | 8.52% | ||
| OM | 8.03% | ||
| PM (TTM) | 6.62% | ||
| GM | 52.65% | ||
| FCFM | 12.42% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.91 | ||
| Debt/EBITDA | 3.93 | ||
| Cap/Depr | 32.68% | ||
| Cap/Sales | 3.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.06% | ||
| Profit Quality | 187.52% | ||
| Current Ratio | 8.37 | ||
| Quick Ratio | 7.12 | ||
| Altman-Z | 5.95 |
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
REPLIGEN CORP (RGEN) has a profitability rating of 6 / 10.
The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 16.45% in the next year.